AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Purple Biotech to Showcase CAPTN-3 Platform at EACR 2025 Congress
ByAinvest
Wednesday, Jun 4, 2025 1:53 pm ET1min read
Purple Biotech will present a poster on its CAPTN-3 tri-specific antibody platform at EACR 2025. The presentation is scheduled for June 17, 2025, during the Immunotherapy session in Lisbon, Portugal. The abstract will be published online post-presentation. Purple Biotech is a clinical-stage biopharmaceutical company focusing on overcoming tumor immune evasion and drug resistance through its developmental therapies.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biopharmaceutical company, has announced that it will present a poster on its novel CAPTN-3 tri-specific antibody platform at the European Association for Cancer Research (EACR) 2025. The presentation is scheduled for June 17, 2025, during the Immunotherapy session in Lisbon, Portugal.The abstract, titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers," will be presented by Dr. Hadas Reuveni, Vice President of Research and Development at Purple Biotech. The abstract will be available online following the presentation [1].
Purple Biotech focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. The company's oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, a novel target for multiple cancer indications. NT219 is a dual inhibitor targeting IRS1/2 and STAT3, showing anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) [1].
The CAPTN-3 platform is a preclinical platform of conditionally activated tri-specific antibodies that engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response [1].
The company's corporate headquarters are located in Rehovot, Israel. For more information, please visit the official website of Purple Biotech [1].
References:
[1] https://www.globenewswire.com/news-release/2025/06/04/3093432/0/en/Purple-Biotech-Announces-Poster-Presentation-at-EACR-2025-on-its-Novel-CAPTN-3-Tri-Specific-Antibody-Platform.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet